Literature DB >> 23862666

Hepatitis C virus infection is not an independent risk factor for obstructive lung disease.

William A Fischer1, Michael B Drummond, Christian A Merlo, David L Thomas, Robert Brown, Shruti H Mehta, Robert A Wise, Greg D Kirk.   

Abstract

Several epidemiological studies have suggested that hepatitis C virus (HCV) infection is associated with the presence of obstructive lung disease (OLD). However, there is a strong link between HCV infection and tobacco abuse, a major risk factor for the development of OLD. In this study we analyzed clinical, laboratory and spirometric data from 1068 study participants to assess whether HCV infection, viremia, or HCV-associated end organ damage were associated with OLD. Demographics, risk behavior, serologic status for HCV and HIV, and spirometric measurements were collected from a cross-sectional analysis of the Acquired Immunodeficiency Syndrome (AIDS) Linked to the IntraVenous Experience (ALIVE) study, an observational cohort of IDUs followed in Baltimore, MD since 1988. Of 1,068 participants, 890 (83%) were HCV positive and 174 (16%) met spirometric criteria for OLD. Factors independently associated with OLD were age and BMI. HCV infection, viral load and HCV-associated end organ damage were similar in participants with and without OLD. In summary, there was no independent association between markers of HCV exposure, chronicity, viremia, or HCV-associated end-organ damage with OLD. Our findings support the strong correlation between HCV status, injection drug use, and smoking. These data suggest that HCV may not be a sole contributor to the increased prevalence of OLD described in previous studies of HCV-infected individuals.

Entities:  

Mesh:

Year:  2013        PMID: 23862666      PMCID: PMC4302731          DOI: 10.3109/15412555.2013.800854

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  29 in total

1.  Bronchoalveolar lavage fluid analysis in individuals with chronic hepatitis C.

Authors:  Ramazan Idilman; Hülya Cetinkaya; Ismail Savaş; Nuray Aslan; Serpil Dizbay Sak; Mehmet Baştemir; Mustafa Sarioğlu; Irfan Soykan; Mithat Bozdayi; Alessandra Colantoni; Olcay Aydintuğ; Kadir Bahar; Ozden Uzunalimoğlu; David H Van Thiel; Numan Numanoğlu; Abdulkadir Dökmeci
Journal:  J Med Virol       Date:  2002-01       Impact factor: 2.327

2.  Bronchoalveolar lavage fluid findings in patients with chronic hepatitis C virus infection.

Authors:  K Kubo; S Yamaguchi; K Fujimoto; M Hanaoka; M Hayasaka; T Honda; T Sodeyama; K Kiyosawa
Journal:  Thorax       Date:  1996-03       Impact factor: 9.139

Review 3.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

4.  Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study.

Authors:  Andrea S Gershon; Laura Warner; Paul Cascagnette; J Charles Victor; Teresa To
Journal:  Lancet       Date:  2011-09-10       Impact factor: 79.321

Review 5.  Hepatitis C virus and the lung: implications for therapy.

Authors:  Jonathan Moorman; Mustafa Saad; Semaan Kosseifi; Guha Krishnaswamy
Journal:  Chest       Date:  2005-10       Impact factor: 9.410

6.  Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection.

Authors:  Gregory D Kirk; Jacquie Astemborski; Shruti H Mehta; Chuck Spoler; Cedric Fisher; Danisha Allen; Yvonne Higgins; Richard D Moore; Nezem Afdhal; Michael Torbenson; Mark Sulkowski; David L Thomas
Journal:  Clin Infect Dis       Date:  2009-04-01       Impact factor: 9.079

7.  Accelerated decline of lung function in COPD patients with chronic hepatitis C virus infection: a preliminary study based on small numbers of patients.

Authors:  Hiroshi Kanazawa; Kazuto Hirata; Junichi Yoshikawa
Journal:  Chest       Date:  2003-02       Impact factor: 9.410

8.  Limited uptake of hepatitis C treatment among injection drug users.

Authors:  Shruti H Mehta; Becky L Genberg; Jacquie Astemborski; Ravi Kavasery; Gregory D Kirk; David Vlahov; Steffanie A Strathdee; David L Thomas
Journal:  J Community Health       Date:  2008-06

9.  Accelerated decline in lung function and impaired reversibility with salbutamol in asthmatic patients with chronic hepatitis C virus infection: a 6-year follow-up study.

Authors:  Hiroshi Kanazawa; Junichi Yoshikawa
Journal:  Am J Med       Date:  2004-06-01       Impact factor: 4.965

10.  Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors.

Authors:  Christine Meffre; Yann Le Strat; Elisabeth Delarocque-Astagneau; Fréderic Dubois; Denise Antona; Jean-Marie Lemasson; Josiane Warszawski; Josiane Steinmetz; Dominique Coste; Jean-François Meyer; Sandrine Leiser; Jean-Pierre Giordanella; René Gueguen; Jean-Claude Desenclos
Journal:  J Med Virol       Date:  2010-04       Impact factor: 2.327

View more
  3 in total

Review 1.  Pulmonary disease in HIV-infected adults in the era of antiretroviral therapy.

Authors:  Meghan E Fitzpatrick; Ken M Kunisaki; Alison Morris
Journal:  AIDS       Date:  2018-01-28       Impact factor: 4.177

2.  Trends in Epidemiology of COPD in HIV-Infected Patients in Spain (1997-2012).

Authors:  Javier de Miguel-Díez; Ana López-de-Andrés; Rodrigo Jiménez-García; Luis Puente-Maestu; Isabel Jiménez-Trujillo; Valentín Hernández-Barrera; Salvador Resino; Alejandro Álvaro-Meca
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

3.  COPD in HIV-Infected Patients: CD4 Cell Count Highly Correlated.

Authors:  Karine Risso; Francine Guillouet-de-Salvador; Laure Valerio; Pascal Puglièse; Alissa Naqvi; Jacques Durant; Elisa Demonchy; Isabelle Perbost; Eric Cua; Charles-Hugo Marquette; Pierre-Marie Roger
Journal:  PLoS One       Date:  2017-01-05       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.